{"id":"any-fda-approved-antipsychotic-agent","safety":{"commonSideEffects":[{"rate":"5–70% depending on agent and dose","effect":"Extrapyramidal symptoms (tremor, rigidity, akathisia)"},{"rate":"10–30%","effect":"Weight gain"},{"rate":"10–25%","effect":"Metabolic syndrome (hyperglycemia, dyslipidemia)"},{"rate":"20–50%","effect":"Prolactin elevation (galactorrhea, sexual dysfunction)"},{"rate":"10–40%","effect":"Sedation"},{"rate":"5–15%","effect":"Orthostatic hypotension"},{"rate":"1–5%","effect":"QT prolongation"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Antipsychotics work primarily by antagonizing dopamine D2 receptors, which reduces excessive dopaminergic signaling implicated in psychosis. Many also block serotonin 5-HT2A receptors and other targets, contributing to efficacy across psychotic and mood disorders. The specific receptor profile varies by agent (typical vs. atypical antipsychotics).","oneSentence":"FDA-approved antipsychotics block dopamine and/or serotonin receptors in the brain to reduce psychotic symptoms and stabilize mood.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:40:48.712Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Schizophrenia"},{"name":"Bipolar disorder (acute mania and maintenance)"},{"name":"Psychotic disorders"},{"name":"Agitation associated with dementia or delirium"}]},"trialDetails":[{"nctId":"NCT02360319","phase":"PHASE4","title":"Comparison of a Long-acting Injectable Antipsychotic vs Clinician's Choice Early in Treatment to Break the Cycle of Relapse in Early Phase Schizophrenics","status":"COMPLETED","sponsor":"Vanguard Research Group","startDate":"2014-12-11","conditions":"Schizophrenia","enrollment":489}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":21,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Any FDA approved antipsychotic agent","genericName":"Any FDA approved antipsychotic agent","companyName":"Vanguard Research Group","companyId":"vanguard-research-group","modality":"Small molecule","firstApprovalDate":"","aiSummary":"FDA-approved antipsychotics block dopamine and/or serotonin receptors in the brain to reduce psychotic symptoms and stabilize mood. Used for Schizophrenia, Bipolar disorder (acute mania and maintenance), Psychotic disorders.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}